Journal article
Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET.
- Altomare D Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
- Ferrari C Unit of Statistics, Saint John of God Clinical Research Centre, Brescia, Italy.
- Festari C Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
- Guerra UP Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy.
- Muscio C Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy; Division of Neurology V-Neuropathology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy.
- Padovani A Centre for Aging Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy.
- Frisoni GB Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Memory Clinic, University Hospital of Geneva, Geneva, Switzerland.
- Boccardi M Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland. Electronic address: marina.boccardi@unige.ch.
- 2018-04-22
Published in:
- Alzheimer's & dementia : the journal of the Alzheimer's Association. - 2018
Alzheimer's disease
Amyloid PET
Appropriate use criteria
Advisory Committees
Aged
Alzheimer Disease
Amyloid beta-Peptides
Brain
Cognitive Dysfunction
Female
Humans
Neuropsychological Tests
Positron-Emission Tomography
English
INTRODUCTION
We test the hypothesis that amyloid-positron emission tomography prescriptions, considered appropriate based on the Amyloid Imaging Taskforce (AIT) criteria, lead to greater clinical utility than AIT-inappropriate prescriptions.
METHODS
We compared the clinical utility between patients who underwent amyloid-positron emission tomography appropriately or inappropriately and among the subgroups of patients defined by the AIT criteria. Finally, we performed logistic regressions to identify variables associated with clinical utility.
RESULTS
We identified 171 AIT-appropriate and 67 AIT-inappropriate patients. AIT-appropriate and AIT-inappropriate cases did not differ in any outcomes of clinical utility (P > .05). Subgroup analysis denoted both expected and unexpected results. The logistic regressions outlined the primary role of clinical picture and clinical or neuropsychological profile in identifying patients benefitting from amyloid-positron emission tomography.
DISCUSSION
Contrary to our hypothesis, also AIT-inappropriate prescriptions were associated with clinical utility. Clinical or neuropsychological variables, not taken into account by the AIT criteria, may help further refine criteria for appropriateness.
We test the hypothesis that amyloid-positron emission tomography prescriptions, considered appropriate based on the Amyloid Imaging Taskforce (AIT) criteria, lead to greater clinical utility than AIT-inappropriate prescriptions.
METHODS
We compared the clinical utility between patients who underwent amyloid-positron emission tomography appropriately or inappropriately and among the subgroups of patients defined by the AIT criteria. Finally, we performed logistic regressions to identify variables associated with clinical utility.
RESULTS
We identified 171 AIT-appropriate and 67 AIT-inappropriate patients. AIT-appropriate and AIT-inappropriate cases did not differ in any outcomes of clinical utility (P > .05). Subgroup analysis denoted both expected and unexpected results. The logistic regressions outlined the primary role of clinical picture and clinical or neuropsychological profile in identifying patients benefitting from amyloid-positron emission tomography.
DISCUSSION
Contrary to our hypothesis, also AIT-inappropriate prescriptions were associated with clinical utility. Clinical or neuropsychological variables, not taken into account by the AIT criteria, may help further refine criteria for appropriateness.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.jalz.2018.02.022
- PMID 29679576
- Persistent URL
- https://sonar.ch/global/documents/53069
Statistics
Document views: 34
File downloads: